Graft-versus-host disease-free, relapse-free, second transplant-free survival in allogeneic hematopoietic cell transplantation for genetic disorders

Koji Kawaguchi^{1

2}, Katsutsugu Umeda^{3

4}, Satoshi Miyamoto^{2

5}, Nao Yoshida^{2

6}, Hiromasa Yabe^{2

7}, Takashi Koike⁷, Michiko Kajiwara⁵, Hiroshi Kawaguchi⁸, Yoshiyuki Takahashi⁹, Masataka Ishimura¹⁰, Hirotoshi Sakaguchi¹¹, Asahito Hama⁶, Yuko Cho¹², Maho Sato¹³, Keisuke Kato¹⁴, Atsushi Sato¹⁵, Koji Kato¹⁶, Ken Tabuchi¹⁷, Yoshiko Atsuta^{18

19}, Kohsuke Imai^{2

5

20}

Affiliations

¹ Department of Hematology and Oncology, Shizuoka Children's Hospital, Shizuoka, Japan.
² Inherited Disorder Working Group of the Japanese Society for Transplantation and Cellular Therapy, Nagoya, Japan.
³ Inherited Disorder Working Group of the Japanese Society for Transplantation and Cellular Therapy, Nagoya, Japan. umeume@kuhp.kyoto-u.ac.jp.
⁴ Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan. umeume@kuhp.kyoto-u.ac.jp.
⁵ Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan.
⁶ Department of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Aichi Medical Center Nagoya First Hospital, Nagoya, Japan.
⁷ Department of Pediatrics, Tokai University School of Medicine, Isehara, Japan.
⁸ Department of Pediatrics, Hiroshima University Graduate School of Biomedical and Health Science, Hiroshima, Japan.
⁹ Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
¹⁰ Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
¹¹ Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
¹² Department of Pediatrics, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
¹³ Department of Hematology/Oncology, Osaka Women's and Children's Hospital, Osaka, Japan.
¹⁴ Division of Pediatric Hematology and Oncology, Ibaraki Children's Hospital, Mito, Japan.
¹⁵ Department of Hematology and Oncology, Miyagi Children's Hospital, Sendai, Japan.
¹⁶ Central Japan Cord Blood Bank, Seto, Japan.
¹⁷ Division of Pediatrics, Tokyo Metropolitan Cancer and Infectious Disease Komagome Hospital, Tokyo, Japan.
¹⁸ Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
¹⁹ Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan.
²⁰ Department of Pediatrics, National Medical Defense College, Tokorozawa, Japan.

PMID: 36797422
DOI: 10.1038/s41409-023-01937-1

Graft-versus-host disease-free, relapse-free, second transplant-free survival in allogeneic hematopoietic cell transplantation for genetic disorders

Koji Kawaguchi et al. Bone Marrow Transplant. 2023 May.

. 2023 May;58(5):600-602.

doi: 10.1038/s41409-023-01937-1. Epub 2023 Feb 16.

Authors

Affiliations

¹ Department of Hematology and Oncology, Shizuoka Children's Hospital, Shizuoka, Japan.
² Inherited Disorder Working Group of the Japanese Society for Transplantation and Cellular Therapy, Nagoya, Japan.
³ Inherited Disorder Working Group of the Japanese Society for Transplantation and Cellular Therapy, Nagoya, Japan. umeume@kuhp.kyoto-u.ac.jp.
⁴ Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan. umeume@kuhp.kyoto-u.ac.jp.
⁵ Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan.
⁶ Department of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Aichi Medical Center Nagoya First Hospital, Nagoya, Japan.
⁷ Department of Pediatrics, Tokai University School of Medicine, Isehara, Japan.
⁸ Department of Pediatrics, Hiroshima University Graduate School of Biomedical and Health Science, Hiroshima, Japan.
⁹ Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
¹⁰ Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
¹¹ Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
¹² Department of Pediatrics, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
¹³ Department of Hematology/Oncology, Osaka Women's and Children's Hospital, Osaka, Japan.
¹⁴ Division of Pediatric Hematology and Oncology, Ibaraki Children's Hospital, Mito, Japan.
¹⁵ Department of Hematology and Oncology, Miyagi Children's Hospital, Sendai, Japan.
¹⁶ Central Japan Cord Blood Bank, Seto, Japan.
¹⁷ Division of Pediatrics, Tokyo Metropolitan Cancer and Infectious Disease Komagome Hospital, Tokyo, Japan.
¹⁸ Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
¹⁹ Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan.
²⁰ Department of Pediatrics, National Medical Defense College, Tokorozawa, Japan.

PMID: 36797422
DOI: 10.1038/s41409-023-01937-1

No abstract available

PubMed Disclaimer

References

1. DeFilipp Z, Hefazi M, Chen YB, Blazar BR. Emerging approaches to improve allogeneic hematopoietic cell transplantation outcomes for nonmalignant diseases. Blood 2022;139:3583–93. - DOI - PubMed
1. Umeda K. Unresolved issues in allogeneic hematopoietic cell transplantation for non-malignant diseases. Int J Hematol. 2022;116:41–7. - DOI - PubMed
1. Umeda K, Imai K, Yanagimachi M, Yabe H, Kobayashi M, Takahashi Y, et al. Impact of graft-versus-host disease on the clinical outcome of allogeneic hematopoietic stem cell transplantation for non-malignant diseases. Int J Hematol. 2020;111:869–76. - DOI - PubMed
1. Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood 2015;125:1333–8. - DOI - PubMed - PMC
1. Inamoto Y, Kimura F, Kanda J, Sugita J, Ikegame K, Nakasone H, et al. Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups. Haematologica 2016;101:1592–602. - DOI - PubMed - PMC

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Graft-versus-host disease-free, relapse-free, second transplant-free survival in allogeneic hematopoietic cell transplantation for genetic disorders

Affiliations

Graft-versus-host disease-free, relapse-free, second transplant-free survival in allogeneic hematopoietic cell transplantation for genetic disorders

Authors

Affiliations

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources